Announcement • Jun 09
Read-Gene S.A., Annual General Meeting, Jun 30, 2026 Read-Gene S.A., Annual General Meeting, Jun 30, 2026. New Risk • Jun 07
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 1.2% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.2% operating cash flow to total debt). High level of non-cash earnings (38% accrual ratio). Minor Risks Revenue is less than US$5m (zł17m revenue, or US$4.5m). Market cap is less than US$100m (zł60.4m market cap, or US$16.4m). New Risk • Feb 24
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 2.4% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (2.4% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Revenue is less than US$5m (zł16m revenue, or US$4.3m). Market cap is less than US$100m (zł68.9m market cap, or US$19.2m). Reported Earnings • Feb 19
Full year 2025 earnings released: EPS: zł0.069 (vs zł0.094 loss in FY 2024) Full year 2025 results: EPS: zł0.069 (up from zł0.094 loss in FY 2024). Revenue: zł15.6m (up 18% from FY 2024). Net income: zł808.3k (up zł1.92m from FY 2024). Profit margin: 5.2% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Feb 11
Read-Gene S.A. to Report Q4, 2025 Results on Feb 13, 2026 Read-Gene S.A. announced that they will report Q4, 2025 results on Feb 13, 2026 New Risk • Feb 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 62% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Revenue is less than US$5m (zł15m revenue, or US$4.3m). Market cap is less than US$100m (zł61.3m market cap, or US$17.2m). Reported Earnings • Nov 18
Third quarter 2025 earnings released Third quarter 2025 results: Revenue: zł3.39m (up 1.6% from 3Q 2024). Net loss: zł237.4k (down 197% from profit in 3Q 2024). Announcement • Nov 12
Read-Gene S.A. to Report Q3, 2025 Results on Nov 14, 2025 Read-Gene S.A. announced that they will report Q3, 2025 results on Nov 14, 2025 Reported Earnings • Aug 14
Second quarter 2025 earnings released Second quarter 2025 results: Revenue: zł3.43m (up 16% from 2Q 2024). Net income: zł199.1k (up zł499.2k from 2Q 2024). Profit margin: 5.8% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings. New Risk • Jul 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 70% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Revenue is less than US$5m (zł14m revenue, or US$3.9m). Market cap is less than US$100m (zł61.5m market cap, or US$16.7m). Buy Or Sell Opportunity • May 27
Now 21% overvalued Over the last 90 days, the stock has fallen 2.6% to zł4.11. The fair value is estimated to be zł3.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has declined by 68%. Reported Earnings • May 19
First quarter 2025 earnings released First quarter 2025 results: Revenue: zł1.47m (down 31% from 1Q 2024). Net loss: zł135.9k (loss narrowed 75% from 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 13
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: zł1.07m (down 49% from 2Q 2023). Net loss: zł333.0k (loss narrowed 53% from 2Q 2023). New Risk • Jul 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 64% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Revenue is less than US$5m (zł11m revenue, or US$2.7m). Market cap is less than US$100m (zł74.3m market cap, or US$18.7m). Announcement • Jun 05
Read-Gene S.A., Annual General Meeting, Jun 26, 2024 Read-Gene S.A., Annual General Meeting, Jun 26, 2024. Reported Earnings • May 20
First quarter 2024 earnings released First quarter 2024 results: Revenue: zł2.12m (up 41% from 1Q 2023). Net loss: zł534.9k (loss widened 20% from 1Q 2023). Reported Earnings • Feb 13
Full year 2023 earnings released: zł0.16 loss per share (vs zł0.018 profit in FY 2022) Full year 2023 results: zł0.16 loss per share (down from zł0.018 profit in FY 2022). Revenue: zł10.1m (up 39% from FY 2022). Net loss: zł1.85m (down zł2.06m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 123 percentage points per year, which is a significant difference in performance. New Risk • Dec 06
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 37% per year over the past 5 years. Minor Risks Revenue is less than US$5m (zł8.5m revenue, or US$2.1m). Market cap is less than US$100m (zł56.4m market cap, or US$14.0m). New Risk • Aug 23
New major risk - Revenue and earnings growth Earnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 16% per year over the past 5 years. Market cap is less than US$10m (zł38.9m market cap, or US$9.47m). Minor Risk Revenue is less than US$5m (zł7.8m revenue, or US$1.9m). New Risk • Aug 14
New major risk - Revenue and earnings growth Earnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Revenue is less than US$5m (zł7.8m revenue, or US$1.9m). Market cap is less than US$100m (zł43.4m market cap, or US$10.6m). Reported Earnings • Aug 14
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: zł2.08m (flat on 2Q 2022). Net loss: zł711.9k (down 290% from profit in 2Q 2022). New Risk • Aug 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Revenue is less than US$5m (zł7.3m revenue, or US$1.8m). Market cap is less than US$100m (zł41.5m market cap, or US$10.2m). Announcement • Jun 04
Read-Gene S.A., Annual General Meeting, Jun 30, 2023 Read-Gene S.A., Annual General Meeting, Jun 30, 2023, at 15:00 Central European Standard Time. Reported Earnings • Feb 12
Full year 2022 earnings released: zł0.015 loss per share (vs zł0.003 profit in FY 2021) Full year 2022 results: zł0.015 loss per share (down from zł0.003 profit in FY 2021). Revenue: zł4.07m (down 37% from FY 2021). Net loss: zł178.6k (down zł216.4k from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 57% per year, which means it is well ahead of earnings. Announcement • Jun 07
Read-Gene S.A., Annual General Meeting, Jun 30, 2022 Read-Gene S.A., Annual General Meeting, Jun 30, 2022, at 12:00 Central European Standard Time. Reported Earnings • May 16
First quarter 2022 earnings released First quarter 2022 results: Revenue: zł1.00m (down 13% from 1Q 2021). Net loss: zł305.8k (down zł342.8k from profit in 1Q 2021). Reported Earnings • Feb 12
Full year 2021 earnings: Revenues in line with analyst expectations Full year 2021 results: Revenue: zł6.45m (up 6.3% from FY 2020). Net income: zł342.5k (down 1.9% from FY 2020). Profit margin: 5.3% (down from 5.8% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Reported Earnings • Nov 18
Third quarter 2021 earnings released The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: zł1.28m (down 14% from 3Q 2020). Net loss: zł608.1k (down 339% from profit in 3Q 2020). Reported Earnings • Aug 21
Second quarter 2021 earnings released The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: zł1.35m (up 90% from 2Q 2020). Net income: zł112.8k (up zł535.4k from 2Q 2020). Profit margin: 8.3% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Is New 90 Day High Low • Feb 11
New 90-day high: zł4.06 The company is up 77% from its price of zł2.30 on 13 November 2020. The Polish market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 21% over the same period. Is New 90 Day High Low • Jan 21
New 90-day high: zł3.02 The company is up 14% from its price of zł2.66 on 23 October 2020. The Polish market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 34% over the same period.